Aspirin Research Today is a free monthly online journal that collates and summarizes the latest research about Aspirin, including details on acetylsalicylic acid, baby aspirin, side effects, overdose, allergy.

Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin.

Selleng K, Selleng S, Raschke R, Schmidt CO, Rosenblood GS, Greinacher A, Warkentin TE

Institute of Immunology and Transfusion Medicine, Ernst-Moritz-Arndt University, Greifswald, Germany.

Platelet adenosine diphosphate (ADP) receptors may play a role in potentiating platelet activation induced by IgG from patients with immune heparin-induced thrombocytopenia (HIT), as shown by previous studies using the ADP receptor antagonists AR-C66096 and ticlopidine. Consistent with these observations, we found that platelet activation by HIT sera is also significantly reduced in patients receiving clopidogrel, an ADP receptor antagonist prodrug now in wide clinical use. Despite these in vitro and ex vivo findings, we observed two patients develop acute HIT while receiving both clopidogrel and aspirin: both patients' sera tested strongly positive in a heparin-dependent washed platelet activation assay (100% serotonin release) and PF4/heparin-enzyme-immunoassay (2.594 and 2.190 absorbance units). Both patients also developed HIT-associated clinical sequelae (acute systemic reaction postintravenous heparin bolus; thrombotic stroke) in association with their episode of HIT. We conclude that combined therapy with aspirin and clopidogrel does not necessarily protect against clinical HIT, at least in patients with HIT antibodies that have strong platelet-activating characteristics.

Published 1 March 2005 in Am J Hematol, 78(3): 188-92.
Full-text of this article is available online (may require subscription).

© 2004-2008 Aspirin Research Today. All Rights Reserved.